Related references
Note: Only part of the references are listed.Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells
S. Kanameishi et al.
ANNALS OF ONCOLOGY (2016)
Abnormalities of the bone marrow immune microenvironment in patients with immune thrombocytopenia
Yang Song et al.
ANNALS OF HEMATOLOGY (2016)
Two cases of immune thrombocytopenia associated with pembrolizumab
Audrey Le Roy et al.
EUROPEAN JOURNAL OF CANCER (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP
Jun Zhong et al.
HEMATOLOGY (2016)
Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma
Benjamin Y. Kong et al.
MELANOMA RESEARCH (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP): Potential Involvement of PD-1 Pathway in ITP Immunopathogenesis
Elif Birtas Atesoglu et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2016)
Current Management of Primary Immune Thrombocytopenia
Drew Provan et al.
ADVANCES IN THERAPY (2015)
Treatment possibilities of ipilimumab-induced thrombocytopenia-case study and literature review
Jindrich Kopecky et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia
Rukhsana Aslam et al.
BLOOD (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
How I treat idiopathic thrombocytopenic purpura (ITP)
DB Cines et al.
BLOOD (2005)
Share Paper
